Enhanced antibody half-life improves in vivo activity. - Wikidata - awgldk - TriplyDB

Enhanced antibody half-life improves in vivo activity.

Enhanced antibody half-life improves in vivo activity.

http://www.wikidata.org/entity/Q40045495

about

Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases Engineering humoral immunity as prophylaxis or therapy Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics Translating basic mechanisms of IgG effector activity into next generation cancer therapies Targeting the Fc receptor in autoimmune disease Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design Engineering a Monomeric Fc Domain Modality by N-Glycosylation for the Half-life Extension of Biotherapeutics Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life Targeting FcRn for the modulation of antibody dynamics Rational protein design: developing next-generation biological therapeutics and nanobiotechnological tools Neonatal Fc receptor and IgG-based therapeutics The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy Pre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinoma HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission Developing the IVIG biomimetic, hexa-Fc, for drug and vaccine applications Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey.Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data.Next generation of antibody therapy for cancer.Biological evaluation of 131I- and CF750-labeled Dmab(scFv)-Fc antibodies for xenograft imaging of CD25-positive tumors.Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor.Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding.Targeting FcRn for therapy: from live cell imaging to in vivo studies in mice.Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor.Engineered Fc based antibody domains and fragments as novel scaffolds.Selection of nanobodies that target human neonatal Fc receptor.Rapid optimization and prototyping for therapeutic antibody-like molecules.A tripartite cocktail of chimeric monoclonal antibodies passively protects mice against ricin, staphylococcal enterotoxin B and Clostridium perfringens epsilon toxin Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis.Engineered monoclonal antibody with novel antigen-sweeping activity in vivo.Clinical ramifications of the MHC family Fc receptor FcRn.Regulation of immune responses by the neonatal fc receptor and its therapeutic implications Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry Strategies for preventing mucosal cell-associated HIV transmission.pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.Characterization and screening of IgG binding to the neonatal Fc receptor.

P2860

Q26783175-CBAFD030-C162-4857-9022-86F23D7656CD Q26800101-B306FA97-9015-4352-945C-988657011235 Q26822421-491D41BB-FC8A-4873-ABC6-AA3CB24F0F55 Q26991899-0AD7BB2A-707C-41A6-8AE7-2421C897AC2A Q27002843-5A946747-8E55-442A-96A4-4172379F7D37 Q27027238-CCD36E30-5D97-4218-8204-7F92D0990A7A Q27644646-167BDF2B-7A34-4634-8625-1949B14A26E6 Q27677555-51CB6C60-E2F2-4391-8D1B-0950F9D5427D Q27681475-AC9B1F71-22E8-4824-A905-AAADE9601EC1 Q28079016-923A13F9-4DDC-4936-BF47-4BC2C03FFC6C Q28080589-2C87DCCA-8892-4E80-96F0-18D65B5197B2 Q28250420-E59F13FD-994D-450A-ABCB-EFF0F67899C2 Q28252134-D00976D2-0C76-4EB2-822F-BAD8E42CCE2B Q28257521-F1445F36-F3A2-494B-BC5A-14BD5F7DECC2 Q28481572-4D555244-54E8-44C5-8BD0-47D403ED20D3 Q28660329-7C7DA7ED-BED4-4260-BD0C-9DA337AAEE69 Q30834514-EB4ADBD6-04C7-43C4-9A15-7D9635ED36B1 Q31091923-1E0750CA-052D-45F6-9174-A7326B795AFA Q31150455-1EC7D790-9211-4C5B-80B2-7D3CCAB43C1E Q33579636-C1CFEBAB-D2D8-4107-95C9-0730A5808A1F Q33597766-C529B835-F4D5-425A-8C88-DE21BE3E1B85 Q33655344-5AC07AEE-8A55-4F12-ABC4-1CDD6BED574D Q33676732-CFBDE90E-D26E-452E-AFD9-165288BE71EF Q33758483-F1BB5864-73F4-4AFC-B399-D8230361EB7A Q34212755-171846C7-5E30-490C-A94A-C825DE5B3403 Q34244234-A08B1C32-670E-45DC-BFBF-5547946512FC Q34289289-0E319CC3-06F9-449A-BA9E-0F64AD8E8EB7 Q34560808-2ADDB5FD-3CDF-4605-84F4-D476B1785C57 Q34580658-07E0E5DD-3EE1-42C0-B6B2-5DE226CB1BC8 Q34588890-4DA649FD-1D99-44BB-9BC5-D3F924BBCAF1 Q34593860-51BE7F5F-3BA0-4004-B099-DC6539D7A8E9 Q34661388-B5F65574-A22E-445C-B1CD-6CEFECEB6457 Q34672043-EC102F57-8BD6-414A-9CE0-5C38B257BF63 Q34718085-52F8C3AE-4E3E-4A81-9D86-0A3B7A43BBED Q34754673-F921AB46-85CC-4965-8E34-5830E69AB81A Q34818194-368F4397-3940-4C32-AC51-84388603AEAB Q34884133-834F9BA1-9749-4F3F-9EF1-2C885D5DD3D5 Q35000010-54A9737D-B0A8-4427-A115-73D1F1047BBD Q35080330-5AC1174A-8A11-4C1D-A0EB-156A20999370 Q35163945-D0719C56-5A2A-432D-845A-6CC7B08F059A

P2860

Enhanced antibody half-life improves in vivo activity.

http://www.wikidata.org/entity/Q40045495

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Enhanced antibody half-life improves in vivo activity.

@en

type

label

Enhanced antibody half-life improves in vivo activity.

@en

prefLabel

Enhanced antibody half-life improves in vivo activity.

@en

P1433

Q40045495-04ED632B-C498-4898-910D-690B8A13A6F5

P1476

Q40045495-8DC0D867-80E7-40BD-9AFB-E697DC1CE3F7

P2093

Q40045495-1368611C-D58A-4D5A-A26C-3320CEE4E4DB

Q40045495-19D550EF-5909-4B37-AB04-D33CDBE62381

Q40045495-953565AF-C029-4351-A67B-EEE18731674D

Q40045495-A9DEF4A3-8757-4380-AF07-500DA22AF17F

Q40045495-C3812FB3-6147-482B-AD25-1B3669EEAE73

Q40045495-C61BA746-63B6-448B-9C14-94DEBCF38094

Q40045495-D3EF2CB5-B263-4B41-8BFF-A6DE5AE9E548

Q40045495-D99C5DF5-BF7B-4046-82A0-E9FC48E34652

Q40045495-FA8FB2DB-BF36-4457-80C9-B67D84BCED67

P2860

Q40045495-0585FD0F-59DB-493C-B94A-534D6BF76EE8

Q40045495-14ABA4A3-B8ED-4A0E-91CF-834C6ACA2B25

Q40045495-1E0DC957-7245-43FF-9546-7CE2237F6DF7

Q40045495-21413EBF-182C-438F-A707-C294367D3775

Q40045495-2EC3454A-4564-47C5-88A4-336440596838

Q40045495-37EB8116-1FDB-4837-B47B-779E1DFF081E

Q40045495-3E72A839-7DD8-4629-8182-B209C25B12CA

Q40045495-7E88841C-6B31-4C3E-9281-27E757A6CA5C

Q40045495-C199848E-CA1B-4903-9D78-AF33035E302A

Q40045495-C233B283-EC9E-450B-A93E-0086F5393539

P2888

Q40045495-42ED0AB9-9AD0-4141-90A8-AB56E3066010

P304

Q40045495-985675FE-51BF-4430-8272-AD6494019E7D

P31

Q40045495-A4B4E6E0-05D4-4DEC-A12A-F10ABA994941

P356

Q40045495-D8090FDF-DA04-41BC-A0D9-C972F90E7582

P433

Q40045495-DDA16214-79B2-4311-B6AB-320E102F9906

P478

Q40045495-B1A410E4-E717-4465-A0FB-58BE64A12B81

P577

Q40045495-C17790B7-9E8B-4EDC-A147-E0A244FC9495

P5875

Q40045495-96EDA720-0117-4C27-9EDD-BA1472EE84CA

P6179

Q40045495-5E8675F1-D59C-43E8-977B-167EE700FF24

P698

Q40045495-EECCD581-DBC9-4314-8953-71CBD111D8AE

P921

Q40045495-6071BA72-B545-47DF-9D07-AE5C6E4D2C8E

P932

Q40045495-A860F14F-6E81-44A0-9B78-A2E55A589CCF

P356

P1433

Nature Biotechnology

P1476

Enhanced antibody half-life improves in vivo activity.

@en

P2093

Aaron K Chamberlain

http://www.w3.org/2001/XMLSchema#string

Derry C Roopenian

http://www.w3.org/2001/XMLSchema#string

Greg A Lazar

http://www.w3.org/2001/XMLSchema#string

Holly M Horton

http://www.w3.org/2001/XMLSchema#string

Irene W L Leung

http://www.w3.org/2001/XMLSchema#string

John R Desjarlais

http://www.w3.org/2001/XMLSchema#string

Jonathan Zalevsky

http://www.w3.org/2001/XMLSchema#string

Sher Karki

http://www.w3.org/2001/XMLSchema#string

Thomas J Sproule

http://www.w3.org/2001/XMLSchema#string

P2860

FcRn: the neonatal Fc receptor comes of age.

Molecular engineering and design of therapeutic antibodies.

Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor.

Engineered human IgG antibodies with longer serum half-lives in primates.

Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma.

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.

Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life.

Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.

Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.

Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).

P2888

P304

157-159

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NBT.1601

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41041520

http://www.w3.org/2001/XMLSchema#string

P6179

1019620179

http://www.w3.org/2001/XMLSchema#string

P698

20081867

http://www.w3.org/2001/XMLSchema#string

P921

P932

2855492

http://www.w3.org/2001/XMLSchema#string